The mechanisms, diagnosis and management of mitral regurgitation in mitral valve prolapse and hypertrophic cardiomyopathy
Authors:
- Mihaela Octavia PopaMPMihaela Octavia Popa
- Irimia Ana MariaIMIrimia Ana Maria
Open Access
- 30 June 2016
- journal article
- review article
- Published by Applied Systems, srl in Discoveries
- Vol. 4 (2) , e61
Abstract
Valvular disease is a frequent cardiac pathology leading to heart failure and, ultimately, death. Mitral regurgitation, defined as the inability of the two mitral leaflets to coapt, is a common valvular disease and a self sustained pathology. A better understanding of the mitral valve histological layers provides a better understanding of the leaflet and chordae changes in mitral valve prolapse. Mitral valve prolapse may occur in myxomatous degenerative abnormalities, connective tissue disorders or in sporadic isolated cases. It is the most common mitral abnormality of non-ischemic cause leading to severe surgery-requiring mitral regurgitation. In addition to standard echocardiographic investigations, newly implemented three-dimensional techniques are being used and they permit a better visualisation, from the so-called 'surgical view', and an improved evaluation of the mitral valve. Hypertrophic cardiomyopathy is the most frequent inherited myocardial disease caused by mutations in various genes encoding proteins of the cardiac sarcomere, leading to a marked left ventricular hypertrophy unexplained by other comorbidities. The pathological echocardiographic hallmarks of hypertrophic cardiomyopathy are left ventricular hypertrophy, left ventricular outflow tract obstruction and systolic anterior motion of the mitral valve. The systolic anterior motion of the mitral valve contributes to the development of mitral regurgitation and further narrows the left ventricular outflow tract, leading to more severe symptomatology. Cardiac magnetic resonance imaging accurately measures the left ventricular mass, the degree of diastolic function and it may also be used to distinguish phenotypic variants. The clinical outcome of patients with these pathologies is mostly determined by the selected option of treatment. The purpose of surgical correction regarding mitral valve involvement is to restore valvular competence. Surgery has proven to be the only useful treatment in preventing heart failure, improving symptomatology and reducing mortality. Our approach wishes to enhance the understanding of the mitral valve's involvement in hypertrophic cardiomyopathy and mitral valve prolapse from genetic, haemodynamic and clinical perspectives, as well as to present novelties in the grand field of treatment.Keywords
This publication has 102 references indexed in Scilit:
- Mechanisms of disease: hypertrophic cardiomyopathyNature Reviews Cardiology, 2011
- Translational Research on the Mitral Valve: from Developmental Mechanisms to New TherapiesJournal of Cardiovascular Translational Research, 2011
- In Vivo Measurement of Mitral Leaflet Surface Area and Subvalvular Geometry in Patients With Asymmetrical Septal HypertrophyCirculation, 2010
- Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodentsJournal of Clinical Investigation, 2010
- Preoperative scallop-by-scallop assessment of mitral prolapse using 2D-transthoracic echocardiographyCardiovascular Ultrasound, 2010
- Periostin shows increased evolutionary plasticity in its alternatively spliced regionBMC Ecology and Evolution, 2010
- Active Adaptation of the Tethered Mitral ValveCirculation, 2009
- Abundance and location of proteoglycans and hyaluronan within normal and myxomatous mitral valvesCardiovascular Pathology, 2009
- Serum response factor orchestrates nascent sarcomerogenesis and silences the biomineralization gene program in the heartProceedings of the National Academy of Sciences, 2008
- Periostin regulates atrioventricular valve maturationDevelopmental Biology, 2008